AlloCure closes $25 million Series B venture financing AlloCure.

Agger. ‘We look forward to the further successful advancement of AC607 with the potential to improve the lives of patients later on.’.. AlloCure closes $25 million Series B venture financing AlloCure, Inc., a clinical stage biotechnology company focused on the treating kidney disease, today announced the closing of a $25 million Series B venture financing. The round included the participation of fresh syndicate member Lundbeckfond Ventures, in addition to previous investors SV Life Sciences and Novo A/S.S.Researchers found that overall survival at 7 years was better among ladies whose systemic treatment complied with guidelines, specifically for those at moderate threat of recurrence.Among those sufferers with moderate threat of recurrence, the 7-year survival was 88 percent for females who received treatment in keeping with guideline suggestions vs. 79 percent among those whose therapy didn’t. Related StoriesMD Anderson study reveals why chemotherapy drugs not effective for many pancreatic malignancy patientsFDA grants accelerated acceptance for Tagrisso to take care of sufferers with advanced NSCLCViralytics enters into medical trial collaboration agreement with MSDIn addition, even more women whose treatment differed from treatment recommendations experienced recurrence by 7 years than those whose therapy adhered to the guidelines.For those at moderate and high risk of recurrence, the recurrence rate at 7 years was 36 percent and 42 percent respectively when treatment did follow guidelines, versus 17 percent and 36 percent when treatment followed guidelines.Dr.